FDA Grants Accentia Biopharmaceuticals Fast Track Status For SinuNaseTM A Drug To Help Chronic Sinusitis

... Accentia Biopharmaceuticals, Inc. (Nasdaq:ABPI) has been notified that the U.S. Food and Drug Administration (FDA) granted Fast Track status to SinuNaseTM, the Company's intranasal Amphotericin B formulation. To the best of the Company's knowledge, SinuNase is the first and only drug candidate for chronic sinusitis (CS) to receive Fast Track status from the FDA... click link for more info. ...